Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 28, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Sexual Arousal Disorder
Interventions
DRUG

Bremelanotide

Trial Locations (20)

Unknown

Medical Affiliated Research Center, Huntsville

Quality of Life Medical & Research Center, LLC, Tucson

University of California, Department of Family and Preventative Medicine, La Jolla

Downtown Women's Health Care, Denver

Coastal Connecticut Research, New London

South Florida Medical Research, Aventura

Clinical Study Center, Fort Myers

Center For Marital and Sexual Health of South Florida, West Palm Beach

Northeast Indiana Research, Fort Wayne

Center for Sexual Medicine at Sheppard Pratt, Baltimore

Advanced Biomedical Research, Inc, Hackensack

The Center for Female Sexuality, Purchase

Wake Research Associates, LLC, Raleigh

Lyndhurst Gynecologic Associates, Winston-Salem

The Ohio State University, Columbus

Medford Women's Clinic, LLP, Medford

Clinical Trials Research Services, LLC, Pittsburgh

Advanced Clinical Therapies, Inc., West Reading

Accelovance, Houston

Women's Clinical Research Center, Seattle

Sponsors
All Listed Sponsors
collaborator

King Pharmaceuticals is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Palatin Technologies, Inc

INDUSTRY